Sarepta Therapeutics Reveals Priority Review Voucher Sale in $102M Deal
Company to invest proceeds in further R&D efforts.
Sarepta Therapeutics, a medical research and drug development company, has announced the sale of its rare disease Priority Review Voucher (PRV), receiving $102 upon completion of the sale. According to the company, it plans on using the money earned from the sale towards continued R&D efforts, supporting the development of more transformative therapies.
Following the FDA’s accelerated approval of Elevidys for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD), Sarepta was awarded the PRV. The program is intended to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.
Reference: Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million. Sarepta. July 5, 2023. Accessed July 7, 2023. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-sale-priority-review-voucher-102?_ga=2.38539747.1595629843.1688746964-1480284062.1688746964
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
